BML Capital Management LLC Invests $699,000 in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

BML Capital Management LLC purchased a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, Holdings Channel reports. The firm purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals makes up approximately 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding.

Pieris Pharmaceuticals Price Performance

NASDAQ PIRS traded down $0.13 on Tuesday, reaching $15.84. The company had a trading volume of 696 shares, compared to its average volume of 47,524. The firm has a market cap of $20.91 million, a price-to-earnings ratio of -0.85 and a beta of 0.66. Pieris Pharmaceuticals, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The business has a 50 day moving average of $16.74 and a two-hundred day moving average of $13.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday.

Pieris Pharmaceuticals Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.